Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Rani Therapeutics Holdings (RANI) over the last 4 years, with Q3 2025 value amounting to $58000.0.

  • Rani Therapeutics Holdings' Amortization of Deferred Charges changed 0.0% to $58000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $232000.0, marking a year-over-year change of 0.0%. This contributed to the annual value of $232000.0 for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Rani Therapeutics Holdings' Amortization of Deferred Charges stood at $58000.0, which was down 0.0% from $58000.0 recorded in Q2 2025.
  • Rani Therapeutics Holdings' 5-year Amortization of Deferred Charges high stood at $58000.0 for Q4 2022, and its period low was $19000.0 during Q3 2022.
  • Moreover, its 4-year median value for Amortization of Deferred Charges was $58000.0 (2022), whereas its average is $55000.0.
  • Within the past 5 years, the most significant YoY rise in Rani Therapeutics Holdings' Amortization of Deferred Charges was 20526.32% (2023), while the steepest drop was 0.0% (2023).
  • Quarter analysis of 4 years shows Rani Therapeutics Holdings' Amortization of Deferred Charges stood at $58000.0 in 2022, then changed by 0.0% to $58000.0 in 2023, then changed by 0.0% to $58000.0 in 2024, then changed by 0.0% to $58000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $58000.0 for Q3 2025, versus $58000.0 for Q2 2025 and $58000.0 for Q1 2025.